AstraZeneca Ends AZD9412 IFN-β Asthma Trial For Redesign, Relaunch

AstraZeneca is stopping a Phase IIa trial assessing in-licensed AZD9412's effect on asthma patients because fewer of them than expected had their condition worsen, making it difficult for the respiratory specialist to gauge the drug's efficiency. AstraZeneca will now re-design the endpoints and resume the study in 2017.